Page 31 - Pfizer
Caplin Steriles gets US FDA approval for generic blood pressure drug
The company has so far developed and filed 13 ANDAs on its own and with partners, and received six approvals
 "Caplin Steriles gets US FDA approval for generic blood pressure drug")
Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge
Excluding special items, Pfizer earned 75 cents per share, topping analysts' average estimate by 13 cents
 "Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge")
Biocon subsidiary acquires research facility from Pfizer Healthcare
Biotechnology major Biocon on Tuesday said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount. Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement. The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said. This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added. The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories. The facility is ...
 "Biocon subsidiary acquires research facility from Pfizer Healthcare")
Sebi imposes Rs 22.7 crore fine on Aurobindo Pharma for insider trading
The order said that the penalty amount will be paid within 45 days of receipt of this order
 "Sebi imposes Rs 22.7 crore fine on Aurobindo Pharma for insider trading")
Pfizer may be talks to merge off-patent drugs business with Mylan
Separation of Pfizer's off-patent business would be a tax-free spin-off
 "Pfizer may be talks to merge off-patent drugs business with Mylan")
Pfizer offers severance package to employees of Chennai, Aurangabad units
The package offers statutory bonus, gratuity and a compensation of 75 days' wages for every completed year of service. An early bird incentive of Rs 7 lakh has also been offered
 "Pfizer offers severance package to employees of Chennai, Aurangabad units")
Aurangabad, Chennai plants may be sold, not shut: Pfizer tells employees
Both sites will immediately cease manufacturing; the company will exit both sites as soon as possible.
 "Aurangabad, Chennai plants may be sold, not shut: Pfizer tells employees")
Pfizer to stop manufacturing operations in Chennai, Aurangabad units
Over 1,700 employees were working in these two facilities
Pfizer Q2 profit dips 13.81% to Rs 958 million, revenue drops marginally
Revenue from operations of the company stood at Rs 5.19 billion in the quarter
Pfizer cuts revenue forecast on supply shortage at sterile-injections biz
Pfizer has been tackling supply shortage issues at its sterile injectable products unit for at least a year
Pfizer replaces long-time CEO Ian Read with veteran Albert Bourla
Pfizer is contending with the expiry of patents on some of its blockbuster drugs
Pfizer stops production at Tamil Nadu plant after 11 USFDA observations
Firm says it is disappointed with the outcome of the inspection
 "Pfizer stops production at Tamil Nadu plant after 11 USFDA observations")
US drugmaker Pfizer says it will split business into three units
The three new units are innovative medicines, established medicines and consumer healthcare
Pfizer rolls back drug price hikes temporarily after talking with Trump
The Trump administration has not yet taken significant action to lower drug prices
Pfizer hits an over two-year high ahead of March quarter results
The stock was up 5% to Rs 2,434 on the BSE in intra-day trade, trading at its highest level since January 4, 2016.
No dearth of suitors for consumer health business, says Pfizer
Pfizer said the supply challenges would have a negative impact of "several hundred million dollars" this year, moderating in 2018
 "No dearth of suitors for consumer health business, says Pfizer")
Pfizer may sell or spin off its $15-billion consumer healthcare business
Germany's Merck KGaA is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion
 "Pfizer may sell or spin off its $15-billion consumer healthcare business")
Patent to Pfizer could delay Indian vaccines for pneumonia
With global pharmaceutical giant Pfizer getting a patent last month for its pneumonia vaccine, Indian companies' plans to introduce cheaper products could get delayed.Pneumonia kills 200,000 children in India every year. The vaccine is available in the private market from two global pharma giants, Pfizer and GlaxoSmithKline (GSK).Pfizer's vaccine, called PCV13 and marketed as Prevnar13, provides protection against 13 strains of the the streptococcus pneumoniae bacteria. GSK's product can provide protection against 10 strains. Four Indian companies - Serum Institute, Panacea Biotec, Biological E and Tergene Biotech - have pneumococcal conjugate vaccine (PCV) products in the pipeline, according to Sathguru Management Consultant, which had earlier this year made a report on the Indian vaccine market for the Confederation of Indian Industry (CII)."Pfizer's patent doesn't cover a mechanism of action and is primarily on formulation of the product. All the four Indian companies with PCV ...
Pfizer buys AstraZeneca's Neksium antacid
Gelusil and Mucaine are two other drugs in the antacid space the company has
Pfizer fined $106 mn for 'unfair' prices of epilepsy drug
Flynn Pharma fined $6.55 million; CMA also ordered the companies to reduce their prices
